EP2255203A2 - Procédé et marqueur permettant de diagnostiquer des maladies et dommages tubulaires rénaux - Google Patents

Procédé et marqueur permettant de diagnostiquer des maladies et dommages tubulaires rénaux

Info

Publication number
EP2255203A2
EP2255203A2 EP09722298A EP09722298A EP2255203A2 EP 2255203 A2 EP2255203 A2 EP 2255203A2 EP 09722298 A EP09722298 A EP 09722298A EP 09722298 A EP09722298 A EP 09722298A EP 2255203 A2 EP2255203 A2 EP 2255203A2
Authority
EP
European Patent Office
Prior art keywords
markers
polypeptide
sample
marker
absence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09722298A
Other languages
German (de)
English (en)
Inventor
Harald Mischak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mosaiques Diagnostics and Therapeutics AG
Original Assignee
Mosaiques Diagnostics and Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mosaiques Diagnostics and Therapeutics AG filed Critical Mosaiques Diagnostics and Therapeutics AG
Priority to EP09722298A priority Critical patent/EP2255203A2/fr
Publication of EP2255203A2 publication Critical patent/EP2255203A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Definitions

  • the present invention relates to the diagnosis of tubular damage and diseases of the kidney, e.g. Debre-de-Toni-Fanconi syndrome, Dent's disease, cystinosis, or acquired forms by the action of drugs, e.g. Cytostatics.
  • tubular kidney diseases represent a growing problem in the aftercare of chemotherapeutic cancer patients.
  • tubular kidney damage and disease is reversible in early stages with mild severity, whereas severe damage persists. Therefore, the early detection of tubular damage to the kidney is very important, so that patients can be given early if appropriate, a corresponding therapy.
  • renal tubular damage is generally based on the determination of glucosuria and low molecular weight proteinuria, serum analysis and clinical examination.
  • Hereditary diseases such as cystinosis and Dent's disease can be genetically diagnosed. Although many different proteins in the urine of patients with tubular damage are detectable, these are rarely or rarely used for diagnosis.
  • J Physiol Renal Physiol 2007, 293, F456-F467 describe the use of 2-dimensional gel electrophoresis followed by mass fingerprinting to identify biomarkers for the diagnosis of renal tubular damage.
  • the focus here is on proteins / peptides with a molecular weight> 10 kDa.
  • the procedure used is associated with a high expenditure of time, which prevents the use in the clinical routine.
  • the object is achieved by a method for the diagnosis of tubular kidney diseases comprising the step of determining the presence or absence or amplitude of at least one polypeptide marker in a urine sample, wherein the polypeptide marker is selected from the markers shown in Table 1 by values for the molecular masses and the migration time are characterized.
  • the evaluation of the measured polypeptides can be based on the presence or absence or amplitude of the markers taking into account the following limits:
  • Specificity is defined as the number of actual negative samples divided by the sum of the number of actual negatives and the number of false positives. A specificity of 100% means that a test identifies all healthy persons as healthy, i. no healthy person is identified as ill. This does not say anything about how well the test detects sick patients.
  • Sensitivity is defined as the number of actual positive samples divided by the sum of the number of actual positives and the number of false positives. Negative. A sensitivity of 100% means that the test detects all patients. He does not say how well the test detects healthy people.
  • markers according to the invention it is possible to achieve a specificity for tubular kidney damage of at least 60, preferably at least 70, more preferably 80, even more preferably at least 90 and most preferably at least 95%.
  • markers according to the invention it is possible to achieve a sensitivity for tubular kidney damage of at least 60, preferably at least 70, more preferably 80, even more preferably at least 90 and most preferably at least 95%.
  • the migration time is determined by capillary electrophoresis (CE) - e.g. in example under point 2 - determined.
  • CE capillary electrophoresis
  • a 90 cm long glass capillary with an inner diameter (ID) of 50 ⁇ m and an outer diameter (OD) of 360 ⁇ m is operated at an applied voltage of 30 kV.
  • the eluent used is, for example, 30% methanol, 0.5% formic acid in water.
  • CE migration time can vary. Nevertheless, the order in which the polypeptide labels elute is typically the same for each CE system used under the conditions indicated. To even out any differences in migration time, the system can be normalized using standards for which migration times are known. These standards may e.g. be the polypeptides given in the examples (see example point 3).
  • the characterization of the polypeptides shown in Tables 1 to 4 was determined by capillary electrophoresis mass spectrometry (CE-MS), a procedure described in detail, for example, by Neuhoff et al. (Rapid Communications in mass spectrometry, 2004, Vol. 20, pages 149-156).
  • CE-MS capillary electrophoresis mass spectrometry
  • the variation the molecular masses between individual measurements or between different mass spectrometers is relatively small with exact calibration, typically in the range of ⁇ 0.1%, preferably in the range of ⁇ 0.05%, more preferably ⁇ 0.03%, even more preferably ⁇ 0, 01% or 0.005%.
  • polypeptide markers according to the invention are proteins or peptides or degradation products of proteins or peptides. They may be chemically modified, e.g. by post-translational modifications such as glycation, phosphorylation, alkylation or disulfide bridging, or by other reactions, e.g. in the context of mining, to be changed. In addition, the polypeptide markers may also be chemically altered as part of the purification of the samples, e.g. oxidized, be.
  • polypeptide markers molecular mass and migration time
  • polypeptides of the invention are used to diagnose tubular kidney disease.
  • Diagnosis is the process of gaining knowledge by assigning symptoms or phenomena to a disease or injury.
  • the presence or absence of certain polypeptide markers is also used differential diagnosis.
  • the presence or absence of a polypeptide marker can be measured by any method known in the art. Methods that can be used are exemplified below.
  • a polypeptide marker is present when its reading is at least as high as the threshold. If its reading is below that, the polypeptide marker is absent.
  • the threshold value can either be determined by the sensitivity of the measurement method (detection limit) or defined based on experience.
  • the threshold value is preferably exceeded if the measured value of the sample for a particular molecule is exceeded. is at least twice as high as that of a blank (eg only buffer or solvent).
  • the polypeptide marker (s) is / are used to measure its presence or absence, the presence or absence being indicative of tubular kidney disease.
  • polypeptide markers which are typically present in individuals with tubular kidney disease, but are less common or non-existent in individuals without tubular kidney disease.
  • amplitude markers can also be used for diagnosis.
  • Amplitude markers are used in a manner that does not determine the presence or absence, but decides the magnitude of the signal (amplitude) in the presence of the signal in both groups.
  • the tables show the mean amplitudes of the corresponding signals (characterized by mass and migration time) over all measured samples. Two nomination procedures are possible to achieve comparability between differently concentrated samples or different measurement methods. In the first approach, all peptide signals of a sample are normalized to a total amplitude of 1 million counts. The respective mean amplitudes of the single markers are therefore given as parts per million (ppm).
  • amplitude markers via an alternative standardization procedure: in this case, all peptide signals of a sample are scaled with a common normalization factor. For this purpose, a linear regression is formed between the peptide amplitudes of the individual samples and the reference values of all known polypeptides. The increase in the regression line just corresponds to the relative concentration and is used as a normalization factor for this sample. The decision to make a diagnosis depends on how high the amplitude of the respective polypeptide markers in the patient sample is compared to the mean amplitudes in the control group or the "sick" group.
  • the value is close to the mean amplitude of the "sick" group, it can be assumed that the presence of a tubular kidney disease, it corresponds more to the mean amplitudes of the control group, is not to be assumed by a tubular kidney disease.
  • the distance to the mean amplitude can be interpreted as a probability of belonging to a group.
  • the distance between the measured value and the mean amplitude may be considered as a probability of belonging to a group.
  • a frequency marker is a variant of the amplitude marker, in which the amplitude is low in some samples. It is possible to convert such frequency markers into amplitude markers in which, in the calculation of the amplitude, the corresponding samples in which the marker is not found, with a very small amplitude - in the range of the detection limit - are included in the calculation.
  • the individual from whom the sample is derived, in which the presence or absence of one or more polypeptide markers is determined may be any individual who may be suffering from tubular renal disease.
  • the subject is a mammal, most preferably a human.
  • the sample measuring the presence or absence of the polypeptide marker (s) of the invention may be any sample recovered from the subject's body.
  • the sample is a sample having a polypeptide composition suitable for making statements about the condition of the individual.
  • it may be blood, urine, synovial fluid, tissue fluid, body secretions, sweat, cerebrospinal fluid, lymph, intestinal, gastric, pancreatic, bile, tears, tissue, sperm, vaginal fluid, or a stool sample.
  • it is a liquid sample.
  • the sample is a urine sample.
  • Urine samples may be known as known in the art.
  • a mid-jet urine sample is used.
  • the urine sample may e.g. by means of a catheter or also with the aid of a urination apparatus, as described in WO 01/74275.
  • the presence or absence of a polypeptide marker in the sample can be determined by any method known in the art suitable for measuring polypeptide markers. Those skilled in such methods are known. In principle, the presence or absence of a polypeptide marker can be determined by direct methods such as e.g. Mass spectrometry, or indirect methods, e.g. by ligands.
  • the sample of the subject eg, the urine sample
  • the treatment may include, for example, purification, separation, dilution or concentration.
  • the processes may, for example, be centrifugation, filtration, ultrafiltration, dialysis, precipitation or chromatographic Methods such as affinity separation or separation by means of ion exchange chromatography, or an electrophoretic separation.
  • the sample is separated by electrophoresis prior to its measurement, purified by ultracentrifugation and / or separated by ultrafiltration into fractions containing polypeptide labels of a specific molecular size.
  • a mass spectrometric method is used to determine the presence or absence of a polypeptide marker, which method may precede purification or separation of the sample.
  • the mass spectrometric analysis has the advantage over current methods that the concentration of many (> 100) polypeptides of a sample can be determined by means of a single analysis. Any type of mass spectrometer can be used. With mass spectrometry, it is possible to routinely measure 10 fmoles of a polypeptide marker, that is, 0.1 ng of a 10 kDa protein with a measurement accuracy of approximately ⁇ 0.01% from a complex mixture. In mass spectrometers, an ion-forming unit is coupled to a suitable analyzer.
  • electrospray ionization (ESI) interfaces are most commonly used to measure ions from liquid samples, whereas the matrix assisted laser desorption / ionization (MALDI) technique is used to measure ions from sample crystallized with a matrix.
  • MALDI matrix assisted laser desorption / ionization
  • TOF time-of-flight
  • electrospray ionization the molecules present in solution i.a. under the influence of high voltage (e.g., 1-8 kV) to form charged droplets which become smaller by evaporation of the solvent.
  • high voltage e.g. 1-8 kV
  • Coulomb explosions lead to the formation of free ions, which can then be analyzed and detected.
  • TOF analyzers have a very high scanning speed and achieve a very high resolution.
  • Preferred methods for determining the presence or absence of polypeptide markers include gas phase ion spectrometry, such as laser desorption / ionization mass spectrometry, MALDI-TOF-MS, SELDI-TOF-MS (Surface Enhanced Laser Desorption Ionization), LC-MS (Liquid Chromatography - mass spectrometry), 2D-PAGE-MS and capillary electrophoresis mass spectrometry (CE-MS). All of the methods mentioned are known to the person skilled in the art.
  • gas phase ion spectrometry such as laser desorption / ionization mass spectrometry, MALDI-TOF-MS, SELDI-TOF-MS (Surface Enhanced Laser Desorption Ionization), LC-MS (Liquid Chromatography - mass spectrometry), 2D-PAGE-MS and capillary electrophoresis mass spectrometry (CE-MS). All of the methods mentioned are known to the person skilled in the art.
  • CE-MS in which capillary electrophoresis is coupled with mass spectrometry. This process is described in detail, for example, in German patent application DE 10021737, in Kaiser et al. (J. Chromatogr. A 1 2003, Vol. 1013: 157-171, and Electrophoresis, 2004, 25: 2044-2055) and in Wittke et al. (J. Chromatogr. A 1 2003, 1013: 173-181).
  • the CE-MS technique allows to determine the presence of several hundreds of polypeptide markers of a sample simultaneously in a short time, a small volume and high sensitivity. After a sample has been measured, a sample of the measured nen polypeptide marker produced. This can be compared with reference patterns of ill or healthy individuals. In most cases it is sufficient to use a limited number of polypeptide markers for diagnosis. More preferred is a CE-MS method which includes CE coupled online to an ESI-TOF-MS.
  • solvents include acetonitrile, methanol and the like.
  • the solvents may be diluted with water and an acid (e.g., 0.1% to 1% formic acid) added to protonate the analyte, preferably the polypeptides.
  • Capillary electrophoresis makes it possible to separate molecules according to their charge and size. Neutral particles migrate at the rate of electroosmotic flow upon application of a current, cations are accelerated to the cathode and anions are retarded.
  • the advantage of capillaries in electrophoresis is the favorable ratio of surface area to volume, which enables a good removal of the Joule heat arising during the current flow. This in turn allows the application of high voltages (usually up to 30 kV) and thus a high separation efficiency and short analysis times.
  • quartz glass capillaries with internal diameters of typically 50 to 75 ⁇ m are normally used. The used lengths are 30-100 cm.
  • the capillaries usually consist of plastic-coated quartz glass.
  • the capillaries may be both untreated, ie show their hydrophilic groups on the inside, as well as be coated on the inside. A hydrophobic coating can be used to improve the resolution.
  • a pressure which is typically in the range of 0-1 psi may also be applied. The pressure can also be created during the separation or changed during the process.
  • the markers of the sample are separated by capillary electrophoresis, then directly ionized and transferred online to a mass spectrometer coupled thereto for detection.
  • polypeptide markers can advantageously be used for diagnosis.
  • Preferred is the use of at least 3, 5, 6, 8, or 10 markers.
  • 20 to 50 markers are used.
  • the at least 1, 3, 5, 6, 8 or 10 markers are selected from the markers 2, 4, 5, 6, 9, 10, 13, 14, 16, 17, 18, 19, 20, 23 , 28, 32, 33, 34, 35, 36, 37, 43, 49, 55, 57, 60, 61, 62, 63, 64, 65, 68, 69, 70, 73, 77, 80, 82, 86 , 88, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 102, 103, 108, 111, 114, 115, 116, 121, 126, 131, 132, 134, 138, 139 , 141, 144, 145, 146, 150, 151, 152, 154, 156, 157, 159, 161, 163, 164, 165, 166, 167, 168, 169, 171.
  • the at least 1, 3, 5, 8 or 10 markers are selected from the markers 2, 17, 19, 32, 43, 60, 63, 65, 68, 80, 82, 86, 88, 91, 96, 97, 98, 99, 111, 115, 138, 139, 159, 171.
  • markers selected from the group of markers 17, 19, 32, 60, 63, 68, 72, 82, 86, 91, 97, 99, 111, 138, 139, 171.
  • Urine was used to detect polypeptide markers for diagnosis. Urine was withdrawn from healthy donors (peer group) and from patients with kidney disease.
  • proteins such as albumin and immunoglobulins, which are also present in urine of patients in higher concentrations, had to be separated by ultrafiltration.
  • 700 .mu.l of urine were removed and treated with 700 .mu.m filtration buffer (2M urea, 1OmM ammonia, 0.02% SDS).
  • 700 .mu.m filtration buffer (2M urea, 1OmM ammonia, 0.02% SDS).
  • sample volumes were ultrafiltered (20 kDa, Sartorius, Gottingen, DE).
  • the UF was carried out at 3000 rpm in a centrifuge until 1.1 ml of ultrafiltrate were obtained.
  • CE-MS measurements were carried out using a capillary electrophoresis system from Beckman Coulter (P / ACE MDQ System, Beckman Coulter Ine, Fullerton, USA) and an Bruker ESI-TOF mass spectrometer (micro-TOF MS, Bruker Daltonik, Bremen, D). carried out.
  • the CE capillaries were purchased from Beckman Coulter, having an ID / OD of 50/360 ⁇ m and a length of 90 cm.
  • the mobile phase for the CE separation consisted of 20% acetonitrile and 0.25% formic acid in water. 30% isopropanol with 0.5% formic acid was used for the sheath flow at the MS, here with a flow rate of 2 ⁇ l / min.
  • the coupling of CE and MS was performed by a CE-ESI-MS Sprayer Kit (Agilent Technologies , Waldbronn, DE). To inject the sample, 1 to max. 6 psi pressure applied, the duration of the injection was 99 seconds.
  • CE separation was performed with a pressure method: 0 psi for 40 minutes, 0.1 psi for 2 minutes, 0.2 psi for 2 minutes, 0.3 psi for 2 minutes, 0.4 psi for 2 minutes, finally 32 min at 0.5 psi.
  • the total duration of a separation run was thus 80 minutes.
  • the "Nebulizer gas” was set to the lowest possible value.
  • the voltage applied to the spray needle to generate the electrospray was 3700 - 4100 V.
  • the remaining settings on the mass spectrometer were optimized according to the manufacturer's instructions for peptide detection. The spectra were recorded over a mass range of m / z 400 to m / z 3000 and accumulated every 3 seconds.
  • ELM sequence: ELMTGELPYSHINNRDQIIFMVGR 23.49 min
  • the proteins / polypeptides are each used in a concentration of 10 pmol / ⁇ l in water.
  • REV "REV”, "ELM”, “KINCON” and “GIVLY” represent synthetic peptides.
  • the most probable assignment is that in which there is a substantially linear relationship between the shift for the peptide 1 and for the peptide 2.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé permettant de diagnostiquer des maladies et dommages tubulaires rénaux qui comprend l'étape de détermination d'une présence ou absence ou amplitude d'au moins trois marqueurs polypeptidiques dans un échantillon d'urine. Les marqueurs polypeptidiques sont sélectionnés parmi ceux qui, dans le tableau 1, sont caractérisés par des valeurs pour les masses moléculaires et le temps de migration.
EP09722298A 2008-03-19 2009-03-19 Procédé et marqueur permettant de diagnostiquer des maladies et dommages tubulaires rénaux Withdrawn EP2255203A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09722298A EP2255203A2 (fr) 2008-03-19 2009-03-19 Procédé et marqueur permettant de diagnostiquer des maladies et dommages tubulaires rénaux

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08153007 2008-03-19
EP08167429 2008-10-23
EP09722298A EP2255203A2 (fr) 2008-03-19 2009-03-19 Procédé et marqueur permettant de diagnostiquer des maladies et dommages tubulaires rénaux
PCT/EP2009/053242 WO2009115570A2 (fr) 2008-03-19 2009-03-19 Procédé et marqueur permettant de diagnostiquer des maladies et dommages tubulaires rénaux

Publications (1)

Publication Number Publication Date
EP2255203A2 true EP2255203A2 (fr) 2010-12-01

Family

ID=40671165

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09722298A Withdrawn EP2255203A2 (fr) 2008-03-19 2009-03-19 Procédé et marqueur permettant de diagnostiquer des maladies et dommages tubulaires rénaux

Country Status (4)

Country Link
US (1) US20120037507A9 (fr)
EP (1) EP2255203A2 (fr)
JP (1) JP2011515672A (fr)
WO (1) WO2009115570A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286602A1 (en) * 2004-05-10 2006-12-21 Harald Mischak Method and markers for the diagnosis of renal diseases
US20100099196A1 (en) * 2007-03-07 2010-04-22 Harald Mischak Process for normalizing the concentration of analytes in a urine sample
EP1972940A1 (fr) * 2007-03-14 2008-09-24 mosaiques diagnostics and therapeutics AG Procédé et marqueur destinés à diagnostiquer des maladies des reins
EP2198305A2 (fr) * 2007-10-09 2010-06-23 Mosaiques Diagnostics And Therapeutics AG Marqueur polypeptidique pour le diagnostic du cancer de la prostate
EP2051078A1 (fr) * 2007-10-19 2009-04-22 mosaiques diagnostics and therapeutics AG Procédé et marqueur destinés à diagnostiquer le diabète sucré
WO2010031822A1 (fr) * 2008-09-17 2010-03-25 Mosaiques Diagnostics And Therapeutics Ag Carcinome à cellules rénales
JP2012531615A (ja) * 2009-07-02 2012-12-10 モザイクス ダイアグノスティクス アンド セラピューティクス アーゲー 急性腎不全を診断するためのプロセス及びマーカー
EP2579033A4 (fr) * 2010-05-31 2013-11-20 Noriaki Tanaka Méthode permettant de déterminer le stade d'une maladie rénale chronique, dispositif afférent, et son procédé de fonctionnement

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6372249B1 (en) * 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
CA2356174A1 (fr) * 1998-12-21 2000-06-29 Monash University Detection et traitement de maladies du rein
US6677114B1 (en) * 1999-04-20 2004-01-13 Target Discovery, Inc. Polypeptide fingerprinting methods and bioinformatics database system
DE10021737C2 (de) * 2000-05-04 2002-10-17 Hermann Haller Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird
WO2002004950A2 (fr) * 2000-07-12 2002-01-17 Werner Naser Evaluation directe de rapports analyte/molecule de reference
US20030003588A1 (en) * 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
DE10304106A1 (de) * 2003-01-31 2004-08-26 Mosaiques Diagnostics And Therapeutics Ag Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird
US7425700B2 (en) * 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
DE10341193A1 (de) * 2003-09-06 2005-03-31 Mosaiques Diagnostics And Therapeutics Ag Vorrichtung und Verfahren zur quantitativen Auswertung der in einer Körperflüssigkeitsprobe enthaltenden Polypeptide sowie Marker zur Erkennung von pathologischen Zuständen
US20050244973A1 (en) * 2004-04-29 2005-11-03 Predicant Biosciences, Inc. Biological patterns for diagnosis and treatment of cancer
US20060286602A1 (en) * 2004-05-10 2006-12-21 Harald Mischak Method and markers for the diagnosis of renal diseases
ATE534750T1 (de) * 2004-07-30 2011-12-15 Adeza Biomedical Corp Onkofetales fibronektin als zervixkarzinom-marker
CA2604037A1 (fr) * 2005-04-07 2006-10-12 Mosaiques Diagnostics And Therapeutics Ag Marqueurs polypeptidiques pour diagnostiquer le cancer de la prostate
EP1757939A1 (fr) * 2005-08-26 2007-02-28 mosaiques diagnostics and therapeutics AG Marqueurs polypeptidiques pour la diagnose du cancer de la vessie
WO2007063090A1 (fr) * 2005-11-30 2007-06-07 Mosaiques Diagnostics And Therapeutics Ag Marqueur polypeptidique pour diagnostiquer et evaluer la stenose du meat de l'uretre
EP1977250A1 (fr) * 2006-01-20 2008-10-08 mosaiques diagnostics and therapeutics AG Méthode et marqueurs pour le diagnostic de maladies rénales
US20100099196A1 (en) * 2007-03-07 2010-04-22 Harald Mischak Process for normalizing the concentration of analytes in a urine sample
EP1972940A1 (fr) * 2007-03-14 2008-09-24 mosaiques diagnostics and therapeutics AG Procédé et marqueur destinés à diagnostiquer des maladies des reins
EP2198305A2 (fr) * 2007-10-09 2010-06-23 Mosaiques Diagnostics And Therapeutics AG Marqueur polypeptidique pour le diagnostic du cancer de la prostate
EP2051078A1 (fr) * 2007-10-19 2009-04-22 mosaiques diagnostics and therapeutics AG Procédé et marqueur destinés à diagnostiquer le diabète sucré
WO2010031822A1 (fr) * 2008-09-17 2010-03-25 Mosaiques Diagnostics And Therapeutics Ag Carcinome à cellules rénales
WO2010079076A2 (fr) * 2008-12-17 2010-07-15 Mosaiques Diagnostics And Therapeutics Ag Maladie polykystique rénale autosomique dominante (adpkd)
JP2012531615A (ja) * 2009-07-02 2012-12-10 モザイクス ダイアグノスティクス アンド セラピューティクス アーゲー 急性腎不全を診断するためのプロセス及びマーカー
EP2478377A2 (fr) * 2009-09-14 2012-07-25 Mosaiques Diagnostics And Therapeutics AG Polypeptide marqueur pour le diagnostic et l'évaluation de maladies vasculaires

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIPL.-ING. THORSTEN KAISER: "Proteomuntersuchung von Körperflüssigkeiten mittels online gekoppelter. Kapillarelektrophorese - Massenspektrometrie als Routineverfahren der Diagnostik", DISSERTATION, 2004 *
HAUBITZ MARION ET AL: "Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy", KIDNEY INTERNATIONAL, NATURE PUBLISHING GROUP, LONDON, GB, vol. 67, no. 6, 1 June 2005 (2005-06-01), pages 2313 - 2320, XP002397413, ISSN: 0085-2538, DOI: 10.1111/J.1523-1755.2005.00335.X *

Also Published As

Publication number Publication date
US20110036717A1 (en) 2011-02-17
WO2009115570A3 (fr) 2009-11-19
JP2011515672A (ja) 2011-05-19
US20120037507A9 (en) 2012-02-16
WO2009115570A2 (fr) 2009-09-24

Similar Documents

Publication Publication Date Title
WO2009115570A2 (fr) Procédé et marqueur permettant de diagnostiquer des maladies et dommages tubulaires rénaux
WO2010031822A1 (fr) Carcinome à cellules rénales
WO2008110593A2 (fr) Procédé et marqueurs pour le diagnostic de maladies rénales
EP1757939A1 (fr) Marqueurs polypeptidiques pour la diagnose du cancer de la vessie
EP1955064A1 (fr) Marqueur polypeptidique pour diagnostiquer et evaluer la stenose du meat de l'uretre
EP1760463A2 (fr) Procédé et dispositif destinés à la détermination qualitative d`un modéle protéique et/ou peptidique d`un échantillon de liquide prélevé sur un corps animal ou human
DE10158860B4 (de) Massenspektrometrische Proteingemischanalyse
WO2006106129A2 (fr) Marqueurs polypeptidiques pour diagnostiquer le cancer de la prostate
WO2011000938A1 (fr) Procédé et marqueur permettant de diagnostiquer une insuffisance rénale aiguë
WO2009050300A1 (fr) Procédé et marqueurs pour diagnostiquer le diabète sucré
EP2478377A2 (fr) Polypeptide marqueur pour le diagnostic et l'évaluation de maladies vasculaires
EP2810077A2 (fr) Marqueurs polypeptidiques pour le diagnostic et l'évaluation de l'insuffisance cardiaque
EP2394171A2 (fr) Maladie polykystique rénale autosomique dominante (adpkd)
WO2009047280A2 (fr) Marqueur polypeptidique pour le diagnostic du cancer de la prostate
WO2007000466A1 (fr) Marqueur polypeptidique servant a detecter le rejet d'un rein greffe a un stade precoce
EP1784649B1 (fr) Marqueurs polypeptidiques pour le diagnostic de l'arteriosclerose
WO2006106115A2 (fr) Marqueur de polypeptide pour le diagnostic d'alzheimer
EP2649450A1 (fr) Procédé et marqueur pour le diagnostic d'un rétrécissement des voies biliaires et d'un cholangiocarcinome à partir de la bile
WO2012123527A1 (fr) Procédé et marqueurs de diagnostic de formes infracliniques et cliniques du rejet tubulo-interstitiel à médiation lymphocytaire t après une transplantation rénale
WO2013150132A2 (fr) Marqueurs polypeptidiques pour diagnostiquer et évaluer des accidents vasculaires cérébraux
DE112015001580T5 (de) Schnelles Verfahren zum Analysieren von Blutproben zur Identifikation von Hämoglobin-Varianten mittels Elektronenübertragungsdissoziation
DE10340521B4 (de) Verfahren selektiver Kapillarelektrophorese
EP1955075A2 (fr) Marqueur polypeptidique pour diagnostiquer et evaluer des maladies vasculaires

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100923

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

17Q First examination report despatched

Effective date: 20110207

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1150663

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140429

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1150663

Country of ref document: HK